Scotiabank raised the firm’s price target on Sabra Health Care to $17 from $15 and keeps a Sector Perform rating on the shares. Scotiabank is adjusting estimates for Real Estate & REITs covered by the firm to reflect Q2 earnings results and recent transactions, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care price target raised to $16 from $14 at Wells Fargo
- Sabra Healthcare REIT Releases Supplemental Investor Package
- Sabra Health Care ups FY24 normalized FFO view to $1.41-$1.44, consensus $1.40
- Sabra Health Care reports Q2 normalized AFFO 36c, consensus 35c
- SBRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?